• Forest Laboratories Inc., of New York, and Gedeon Richter plc, of Budapest, Hungary, said Forest submitted a new drug application for cariprazine, a dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors, for use in schizophrenia and bipolar mania. Forest licensed Cariprazine rights in the U.S. and Canada.

• Pfizer Inc., of New York, said it completed its acquisition of Cupertino, Calif.-based NextWave Pharmaceuticals Inc., a privately held specialty pharma firm developing products for attention deficit hyperactivity disorder (ADHD). Upon the close of the transaction, Pfizer holds exclusive North American commercialization rights to Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension, a once-daily liquid medication for ADHD. Quillivant gained FDA approval in September.